Andere talen Adverum Biotechnologies, Inc.

Aandelen

ADVM

US00773U2078

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 18-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
11,15 ^USD	-1,76%		-6,85%	+48,11%

21/03	Adverum Biotechnologies dient een aanvraag in voor $200 miljoen gemengde Shelf	MT
19/03	ADVERUM BIOTECHNOLOGIES, INC. : RBC Capital Markets vindt het aandeel niet inspirerend	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Adverum Biotechnologies Files $200 Million Mixed Shelf	21/03
Adverum Biotechnologies: Q4 Earnings Snapshot	18/03
Adverum Biotechnologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	18/03
Adverum Biotechnologies, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	18/03
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates	18/03
Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference	28/02
Adverum Biotechnologies, Inc. announced that it has received $127.5 million in funding from a group of investors	21/02
Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference	12/02
Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD	08/02
Adverum Biotechnologies, Inc. Announces Positive Preliminary Efficacy and Safety Data from Luna Phase 2 Trial of Ixo-Cov in Patients with Wet AMD	08/02
4D Molecular soars as mid-stage data for eye disease therapy 'checks all boxes'	05/02
Adverum Biotechnologies Announces $127.5 Million Private Placement Financing	05/02
Adverum Biotechnologies, Inc. announced that it expects to receive $127.5 million in funding from a group of investors	05/02
Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024	01/02
Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer	29/01
Adverum Biotechnologies, Inc. Appoints Romuald Corbau as Chief Scientific Officer and Member of Executive Committee	29/01
Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society	07/12
Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference	28/11
Adverum Biotechnologies: Q3 Earnings Snapshot	09/11
Adverum Biotechnologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Adverum Biotechnologies, Inc.

Aandelen

ADVM

US00773U2078

Andere talen

Filters